Updates are available Correction dated 2016-07-25

Click to view Correction: https://doi.org/10.1186/s12885-016-2559-8

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

Crossref DOI link: https://doi.org/10.1186/s12885-016-2440-9

Published Online: 2016-07-07

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark